241 related articles for article (PubMed ID: 26159502)
1. Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: Opportunities for antimicrobial stewardship.
Havey TC; Hull MW; Romney MG; Leung V
Am J Infect Control; 2015 Sep; 43(9):946-50. PubMed ID: 26159502
[TBL] [Abstract][Full Text] [Related]
2. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
Siami FS; LaFleur BJ; Siami GA
Clin Ther; 2002 Jan; 24(1):59-72. PubMed ID: 11833836
[TBL] [Abstract][Full Text] [Related]
3. Knowledge, attitudes, and behaviors regarding piperacillin-tazobactam prescribing practices: results from a multicenter study.
Antoine TL; Curtis AB; Blumberg HM; Desilva K; Fransua M; Gould CV; King M; Kraman AA; Pack J; Ribner B; Seybold U; Steinberg JP; Wells JB; Sinkowitz-Cochran RL; Cardo D; Jernigan JA; Gaynes RP
Infect Control Hosp Epidemiol; 2006 Nov; 27(11):1274-7. PubMed ID: 17080393
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
5. Piperacillin-Tazobactam Usage at a Tertiary Pediatric Hospital: An Antimicrobial Stewardship Review.
Janowski AB; Michaels MG; Martin JM; Green MD
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):342-5. PubMed ID: 26407269
[TBL] [Abstract][Full Text] [Related]
6. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program.
Liu P; Ohl C; Johnson J; Williamson J; Beardsley J; Luther V
BMC Infect Dis; 2016 Dec; 16(1):751. PubMed ID: 27955625
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.
Takimoto K; Wang Q; Suzuki D; Katayama M; Hayashi Y
Expert Opin Pharmacother; 2017 Jul; 18(10):1027-1034. PubMed ID: 28627952
[TBL] [Abstract][Full Text] [Related]
8. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
[TBL] [Abstract][Full Text] [Related]
10. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
Siami G; Christou N; Eiseman I; Tack KJ;
Antimicrob Agents Chemother; 2001 Feb; 45(2):525-31. PubMed ID: 11158750
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
Kamata K; Suzuki H; Kanemoto K; Tokuda Y; Shiotani S; Hirose Y; Suzuki M; Ishikawa H
J Infect Chemother; 2015 Aug; 21(8):596-603. PubMed ID: 26070781
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial stewardship in the treatment of skin and soft tissue infections.
Gibbons JA; Smith HL; Kumar SC; Duggins KJ; Bushman AM; Danielson JM; Yost WJ; Wadle JJ
Am J Infect Control; 2017 Nov; 45(11):1203-1207. PubMed ID: 28732743
[TBL] [Abstract][Full Text] [Related]
13. Clinical Effect and Efficacy Factors of Modified Piperacillin-Tazobactam Dosing Regimens in Abdominal Tumor Patients with Post-Operative Pneumonia.
Yang Y; Lu Y; He X; Zhao H; Wang D; Wang W
Surg Infect (Larchmt); 2017; 18(2):99-104. PubMed ID: 27696986
[TBL] [Abstract][Full Text] [Related]
14. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Hou F; Li J; Gao L; Chen Y
Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
[TBL] [Abstract][Full Text] [Related]
17. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
[TBL] [Abstract][Full Text] [Related]
18. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
Amara S; Adamson RT; Lew I; Huang X
Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
[TBL] [Abstract][Full Text] [Related]
19. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Lee J; Oh CE; Choi EH; Lee HJ
Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
[TBL] [Abstract][Full Text] [Related]
20. Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections.
Bassotti G; Chistolini F; Sietchiping-Nzepa F; De-Roberto G; Morelli A
World J Gastroenterol; 2004 Aug; 10(15):2281-3. PubMed ID: 15259083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
